reported two cases of V3-7-RF in monoclonal B-cell lymphocytosis.
In this study, we analyzed HCDR3 amino acid sequences of 81 IGHV3-7-expressing CLL and identified 3 cases with strong homology to 25 previously reported V3-7-RFs from both healthy and malignant B-cells (Table 1, Supplementary Table 1 ). These 25 V3-7-RF cases include 9 with proven RF-activity in vitro. The three newly found CLL cases, CLL81, CLL311 and CLL416, utilized the IGHD3-22 gene segment and the IGHJ3 segment shared by 15/24 and 22/24 of V3-7-RFs, respectively. The CLL V3-7-RFs displayed 470% of homology with a V3-7-RF HCDR3 consensus sequence, defined by the amino acids used by the majority of V3-7-RF cases (Table 1) . Of note, the V3-7-RFs also shared amino acids encoded by non-templated N-region nucleotides ( Figure 1a) . Two of the newly identified CLL V3-7-RF cases (CLL81 and CLL416) expressed the stereotyped IGKV3-15 Ig light chain (IgV L ) reported in 10/10 V3-7-RF cases (Table 1 ). In CLL311, the V3-7-RF Ig heavy chain (IgV H ) was paired with an IGKV3-20-encoded IgV L . Remarkably, similar IGKV3-20 rearrangements were found in the other groups of stereotyped RFs.
The CLL V3-7-RFs were heavily mutated (94.5±1.9% average homology to the IGHV3-7 germline) and shared replacement mutations Q58P, Y66F and Q90E (Figure 1a and Supplementary  Table S2 ). Identical somatic mutations are also frequent among Table S2 ). In addition, all CLL V3-7-RFs shared silent mutations at codon 40, which encodes a serine (S40). None of the 23 non-CLL V3-7-RFs carried replacement mutations at S40 either, whereas replacement mutations at S40 were common in the entire cohort of IGHV3-7-expressing CLL (19% of cases) (Supplementary Table S2 ), suggesting that the serine at this position is important for IgG reactivity.
To prove RF-activity, we recombinantly produced the BCR of CLL81 as soluble IgM as described in the Supplementary methods. CLL81 soluble IgM indeed clearly bound to IgG in enzyme-linked immunosorbent assay (ELISA), apparently with higher affinity than V3-7-RFs of two MZBCLs (M5 and M6). Soluble IgM of two unrelated IGHV3-7-expressing CLL did not bind to IgG in ELISA (Figure 1c ). Binding to IgG was abolished when either the IgV H was replaced with an unrelated IGHV3-7 or when the endogenous IgV L was replaced with that of an unrelated CLL (Figure 1d) , showing that the combination of Ig heavy and light chains in V3-7-RF is selected for IgG-binding capability.
Several lines of evidence suggest a role for antigen-dependent growth of leukemic cells in CLL. Direct proof, however, is lacking, as the natural ligands of CLL BCRs are generally not known. Now able to address this issue, we found that stimulation of primary cells of patient CLL81 with IgG-aggregates (a model for immune-complexes) induces proliferation in a proportion of CD19 þ CD5 þ tumor cells (Figure 1e ), whereas IgG-aggregates did not induce proliferation of IgV H -mutated control CLL cells (Figure 1f ). This indicates that at least a proportion of cells express functionally proficient BCRs, implying that interactions with IgG-containing immune complexes may drive proliferation of leukemic cells in vivo as well.
RF-expressing B-cell lymphomas are associated with Sjö gren's syndrome or infections (that is, HCV, Helicobacter pylori and Chlamydophila psittaci infection), 12 suggesting that RF-specificity might provide a growth advantage within the context of chronic inflammation. Serological analysis of patient CLL81 did not reveal RFs or antibodies for HCV, citrullinated protein or nuclear components (data not shown), suggesting that this case is not associated with HCV infection or auto-immune diseases.
In general, CLL-like stereotyped BCR sequences are rare in B-cells of healthy donors. [13] [14] [15] Interestingly, we identified two V3-7-RFs (UN_18102 and UN_35230) among 1080 IGHV3-7 BCR sequences obtained from healthy donors (Table 1 and Supplementary Table S1 ). These V3-7-RFs may have arisen as a by-product of a vaccination with pneumovax II (Sanofi Pasteur MSD, Maidenhead, UK) and influvac (Solvay, Southampton, UK), received 28 days earlier. V3-7-RFs have also been reported in healthy donors with a history of tuberculosis and after immunization with mismatched RBCs. It is conceivable that conditions that induce inflammation and high levels of immune-complexes drive expansion of RF B-cell clones with a subsequent risk of genetic derailment.
In conclusion, we have identified a new subset of CLL expressing stereotyped IGHV3-7-encoded BCRs. These BCRs display CDR3 homology with previously reported RFs and specifically bind IgG in ELISA. Binding of the IgG-epitope requires both the stereotyped IGHV3-7 heavy chain as well as the stereotyped IGKV3-15 light chain. Most importantly, we show that interaction of the V3-7-RF-expressing leukemic cells with their cognate antigen induces proliferation, providing proof of concept for antigen-sustained tumor cell expansion.
